A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)

Clinical trial NCT06843447 · RECRUITING

Trial details

NCT number: NCT06843447
Sponsor: Merck Sharp & Dohme LLC
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Ovarian Cancer Recurrent

Start date: 2025-04-15
Primary completion: 2029-03-27
Enrollment: 460

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.